XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib
نویسندگان
چکیده
منابع مشابه
WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance
Cisplatin is one of the most commonly used therapeutic drugs for cancer therapy, yet prolonged cisplatin treatment frequently results in drug resistance. To enhance therapeutic effect of cisplatin, we conducted a high throughput screening using a kinase library containing 704 kinases against triple negative breast cancer (TNBC) cells. We demonstrated that cisplatin activates ATR, CHK1 and WEE1,...
متن کاملRAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib.
A PARP inhibitor is a rationally designed targeted therapy for cancers with impaired DNA repair abilities. RAD51C is a paralog of RAD51 that has an important role in the DNA damage response. We found that cell lines sensitive to a novel oral PARP inhibitor, olaparib, had low levels of RAD51C expression using microarray analysis, and we therefore hypothesized that low expression of RAD51C may ha...
متن کاملClinicopathological comparison of triple negative breast cancers with non-triple negative breast cancers in a hospital in North India.
INTRODUCTION Breast cancer is the second most common cancer worldwide (1.3 million cases, 10.9%) and ranks 5 th as cause of death from cancer overall (458,000 cases, 6.1%). Triple-negative breast cancer (TNBC) is a subtype of breast cancer with characteristic biological and pathological features. Among the subgroups of breast cancer, triple negative cancer is particularly feared because it is a...
متن کاملPKCα and ERβ Are Associated with Triple-Negative Breast Cancers in African American and Caucasian Patients
Although the incidence of breast cancer in the United States is higher in Caucasian women compared with African American women, African-American patients have more aggressive disease as characterized by a higher percentage of triple-negative breast cancers (TNBCs), high-grade tumors, and a higher mortality rate. PKCα is a biomarker associated with endocrine resistance and poor prognosis and ERβ...
متن کاملThe omics of triple-negative breast cancers.
BACKGROUND Triple-negative breast cancers (TNBC) do not represent a single disease subgroup and are often aggressive breast cancers with poor prognoses. Unlike estrogen/progesterone receptor and HER2 (human epidermal growth factor receptor 2) breast cancers, which are responsive to targeted treatments, there is no effective targeted therapy for TNBC, although approximately 50% of patients respo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Therapeutic Advances in Medical Oncology
سال: 2020
ISSN: 1758-8359,1758-8359
DOI: 10.1177/1758835920974201